# US 5,702,946 A · Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,702,946 A
- Document ID: US5702946A
- Status: Granted
- Kind: A
- Application number: 08/398,611
- Filed: 1995-03-01
- Granted: 1997-12-30
- Earliest claimed: 1994-03-03
- Assignees: Genentech, Inc.
- Inventors: Claire M. Doerschuk; Sherman Fong; Caroline Alice Hebert; Kyung Jin Kim; Steven R. Leong
- Web page: https://patentgrep.com/patent/US5702946A

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Anti-IL-8 monoclonal antibodies are described for use in diagnostic applications and in the treatment of inflammatory disorders such as inflammatory bowel disease and bacteria pneumonias.

## Claims

### Claim 1

An anti-IL-8 monoclonal antibody, wherein the antibody comprises an antigen binding site comprising the complementarity determining regions of the light chain polypeptide of FIG. 24 (SEQ ID NO:48) and the complementarity determining regions of the heavy chain polypeptide of FIG. 25 (SEQ ID NO:50).

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody is the monoclonal antibody 6G4.2.5 having ATCC Accession No. HB 11722.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the antibody is chimeric.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the antibody is humanized.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a first variable region and a second variable region, wherein the first variable region comprises the amino acid sequence of amino acids 1-114 set forth in FIG. 24 (SEQ ID NO:48) and the second variable region comprises the amino acid sequence of amino acids 1-122 set forth in FIG. 25 (SEQ ID NO:50).

### Claim 6

Plasmid pantiIL-8.2 having ATCC Accession No. 97056.

### Claim 7

Plasmid p6G425chim2 having ATCC Accession No. 97055.

### Claim 8

Chimeric fab encoded by p6G425chim2 having ATCC Accession No. 97055.

### Claim 9

An antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, and F(ab').sub.2, wherein the antibody fragment comprises the complementarity determining regions of the light chain polypeptide of FIG. 24 (SEQ ID NO:48) and the complementarity determining regions of the heavy chain polypeptide FIG. 25 (SEQ ID NO:50).

### Claim 10 (depends on 9)

The antibody fragment of claim 9, wherein the antibody fragment is humanized.

### Claim 11 (depends on 9)

The antibody fragment of claim 9, wherein the antibody fragment is a F(ab').sub.2.

### Claim 12 (depends on 11)

The antibody fragment of claim 11, wherein the F(ab').sub.2 comprises the variable regions of the light chain polypeptide of FIG. 24 (SEQ ID NO:48) and the heavy chain polypeptide of FIG. 25 (SEQ ID NO:50).